Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

AVAiL Trial Negative for Overall Survival Benefit
Author
Howard (Jack) West, MD

We got some big news in the form of a press release today: avastin (bevacizumab) didn't produce a survival benefit in the European AVAiL (AVAstin in Lung Cancer) trial of cisplatin/gemcitabine with or without avastin at either a higher dose (15 mg/kg IV every three weeks) or a lower dose (7.5 mg/kg IV every three weeks):

AVAiL trial schema

(Click on image to enlarge)

We learned initially that AVAiL was positive for an improvement in progression-free survival (PFS) with cisplatin/gemcitabine/avastin vs. the same chemo alone from a press release (post here). A subsequent presentation of the trial at ASCO (abstract here)confirmed that each of the two doses improved PFS, but if anything the improvement was more robust with the lower dose of avastin:

AVAiL PFS

At the time of the ASCO presentation, the sponsor company (Roche, which markets avastin in Europe) didn't have mature data on overall survival for the trial, so this was not reported.

But today we received word that there was no overall survival benefit for avastin on this trial, for which PFS was the primary endpoint. In fact, all of the groups did unusually well, with a median survival of more than a year.

So where does this leave us? I don't think it necessarily changes our treatment standards, but it is certainly a disappointment for avastin. We still have evidence that avastin improved survival when given at the 15 mg/kg dose every three weeks with carbo/taxol (abstract here). But you'd hope that the benefit of avastin would be enough to improve survival in another trial. I suspect that the very favorable survival in all groups was a combination of a selected group with a modestly better prognosis (adenocarcinoma, no brain metastases, no prior heart disease or blood clots) and who received the benefit of increasingly helpful treatments after first line that led to patients on chemo alone who started with a lower response rate and progression-free survival but did well enough to catch up with the avastin groups. This is similar to the results for women on the initial ECOG trial with carbo/taxol, which showed that women receiving chemo/avastin had a much better PFS and response rate but the same overall survival as recipients of chemo alone. But if you can "rescue" patients to do as well in the end by giving later treatments, with less risk of a tragic bleeding complication or the high cost of avastin (I saw a patient today who is paying $2400 per three week cycle as a copay), it raises the question of whether that treatment is clearly necessary.

In the meantime, I'm inclined to continue to offer avastin, preferentially with carbo/taxol, and at the FDA-approved dose of 15 mg/kg. I would say, though, that with the negative survival data and the suggestion that the lower dose, if anything, looked more favorable than the standard, higher dose, I would consider the question of dose and clear value for avastin to be more questionable than previously. And when we throw in the fact that erbitux (cetuximab) has also recently been reported to improve survival when given with standard chemotherapy, I suspect we're going to see a further erosion of the fair consensus we've had. Stay tuned.

Next Previous link

Previous PostNext Post

Related Content

Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.
Image
Terapias Dirigidas de Cancer de Pulmón 2024
Video
La Dra. Estelamari Rodríguez presenta información básica sobre el NSCLC EGFR+ y analiza la importancia de las pruebas de biomarcadores en el cáncer de pulmón y ofrece una descripción general de las opciones de tratamiento para la enfermedad EGFR+.  Para ver la playlist completa, de click aquí.        

Forum Discussions

Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...

Hi Bluebird,  Welcome to GRACE.  I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had. 

 

A CT would be...

Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...

Hi and welcome to GRACE.  I'm sorry to know you are entering a new stage.  I'm not about to comment just now but wanted to let you know I see your...

Edit to say, we can't give advice but we can comment with views and facts.  :)

 

My first thought is to ask if she has been seen at a large...

Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...

Recent Comments

JOIN THE CONVERSATION
Tagrix FDA Approval
By mariachristian on
Hi Judy! It is so good to…
By JanineT GRACE … on
Tagrix vs Tagrisso
By Dipakchavan on
Hello Linda, my name is…
By AlexandraGBeneke on